Enveric Biosciences to Present at the 6th Annual Neuroscience Innovation Forum and Biotech Showcase during "J.P. Morgan Health Care Week 2023"

Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB) announced its participation at the 6th Annual Neuroscience Innovation Forum and Biotech Showcase during the 41st Annual J.P. Morgan Health Care Conference in San Francisco from January 9-12, 2023. Dr. Joseph Tucker, CEO, will present the company's advancements in therapeutics addressing anxiety, depression, and addiction disorders. The Neuroscience Forum presentation is scheduled for January 8 at 1:30 PM PT, while the Biotech Showcase will take place on January 10 at 10:00 AM PT. Enveric leverages its unique Psybrary™ platform to develop innovative small-molecule therapeutics.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, announced today that the company will present at the 6^th Annual Neuroscience Forum and the Biotech Showcase™. Both events will be held live and are scheduled to coincide with the 41^st Annual J.P. Morgan Health Care Conference in San Francisco, January 9-12, 2023.

Details of the presentations are as follows:

Event:		6th Annual Neuroscience Innovation Forum
Date/Time:		January 8, 2023 at 1:30 PM PT
Location:		Marines Memorial Club, San Francisco, CA - Track D, Room Heritage
Website:		https://www.sachsforum.com/6nif-about.html
Event:		Biotech Showcase
Date/Time:		January 10, 2023 at 10:00 AM PT
Location:		Hilton Union Square, San Francisco, CA - Yosemite A
Website:		https://informaconnect.com/biotech-showcase/

During both presentations, Dr. Joseph Tucker, CEO of Enveric Biosciences will highlight Enveric’s experienced management team, recent corporate achievements, and the company’s robust pipeline of development programs targeting unmet needs in anxiety, depression and/or addiction disorders.

Throughout the week, members of the Enveric management team will participate in one-on-one meetings at the Hotel Fusion on 140 Ellis Street. To request a meeting, please email dboateng@tiberend.com.

About Enveric Biosciences

Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders. Leveraging its unique discovery and development platform, The Psybrary™, Enveric has created a robust Intellectual Property (IP) portfolio of New Chemical Entities (NCEs) for specific mental health indications or physical ailments. Enveric’s lead program, the EVM201 Series, comprises next-generation synthetic psilocybin analogues that are considered prodrugs of the active metabolite, psilocin. Enveric is initially developing EVM201 for the treatment of anxiety disorder. Enveric is also advancing its third generation of therapeutics, the EVM301 Series, to offer a holistic approach for treating central nervous system disorders. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada. For more information, please visit www.enveric.com.

Forward-Looking Statements

This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans,”” expects” or “does not expect,” “proposed,” “is expected,” “budgets,” “scheduled,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. Forward-looking statements consist of not purely historical statements, including any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to successfully spin-off its cannabinoid assets; the ability to achieve the value creation contemplated by technical developments; the impact of the novel coronavirus (COVID-19) on Enveric’s ongoing and planned clinical trials; the geographic, social and economic impact of COVID-19 on Enveric’s ability to conduct its business and raise capital in the future when needed; delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; Enveric’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to Enveric’s products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission (SEC), including Enveric’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221220005782/en/

Investor Relations

Tiberend Strategic Advisors, Inc.

Daniel Kontoh-Boateng

(862) 213-1398

dboateng@tiberend.com

Media Relations

Tiberend Strategic Advisors, Inc.

Casey McDonald

(646) 577-8520

cmcdonald@tiberend.com

Source: Enveric Biosciences

FAQ

What events is Enveric Biosciences participating in January 2023?

Enveric Biosciences is presenting at the 6th Annual Neuroscience Innovation Forum and the Biotech Showcase during the 41st Annual J.P. Morgan Health Care Conference.

When is Enveric's presentation at the Neuroscience Forum?

Enveric's presentation at the Neuroscience Forum is on January 8, 2023, at 1:30 PM PT.

What is the date and time for Enveric's Biotech Showcase presentation?

The Biotech Showcase presentation by Enveric is scheduled for January 10, 2023, at 10:00 AM PT.

Where will Enveric's presentations be held?

The Neuroscience Forum presentation will be at the Marines Memorial Club in San Francisco, CA, and the Biotech Showcase will be at the Hilton Union Square in San Francisco, CA.

What will Dr. Joseph Tucker present at the events?

Dr. Joseph Tucker will discuss Enveric's management team, recent achievements, and its development programs focusing on anxiety, depression, and addiction disorders.

How can I request a one-on-one meeting with Enveric management during the conference?

To request a meeting with Enveric management, email dboateng@tiberend.com.